AVENUE THERAP. DL-,0001 Aktie - Unternehmensdaten & Kurse - US05360L3042 | MoneyPeak

AVENUE THERAP. DL-,0001

Share · US05360L3042 · ATXI · A3DWU7 (XNMS)

Analyst Grade Summary

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

0

1

0

0

0

No Price

31.10.2025 19:49

Current Prices from AVENUE THERAP. DL-,0001

Exchange	Ticker	Currency	Last Trade	Price	Daily Change
NASDAQ	ATXI	USD	31.10.2025 19:49	0,72 USD	0,005 USD +0,67 %

Share Float & Liquidity

Free Float 88,98 %

Shares Float 2,83 M

Shares Outstanding 3,18 M

Company Profile for AVENUE THERAP. DL-,0001 Share

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Get up to date insights from finAgent about AVENUE THERAP. DL-,0001

Company Data

Name AVENUE THERAP. DL-,0001

Company Avenue Therapeutics, Inc.

Symbol ATXI

Website https://www.avenuetx.com

Primary Exchange

Frankfurt

WKN A3DWU7

ISIN US05360L3042

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Alexandra MacLean

Country United States of America

Currency EUR

Employees 0,0 T

Address 1140 Avenue of the America, 10036 New York City

IPO Date 2017-06-27

Ticker Symbols

Name	Symbol
NASDAQ	ATXI

More Shares

Investors who hold AVENUE THERAP. DL-,0001 also have the following shares in their portfolio:

IMMUNOVIA AB Share

Pacifico Acquisition Corp. Share

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog

Im App Store herunterladen

Bei Google Play herunterladen

All rights reserved © LCP GmbH 2025